Catalyst Pharmaceuticals, Inc.
US ˙ NASDAQCM ˙ US14888U1016 ˙ Medical Devices
DIESES SYMBOL IST NICHT MEHR AKTIV

SecurityCPRX / Catalyst Pharmaceuticals, Inc.
InstitutionGMSMX - GuideMark(R) Small/Mid Cap Core Fund Service Shares
Latest Disclosed Ownership6,138 shares
Latest Disclosed Value $ 151,976
GMSMX - GuideMark(R) Small/Mid Cap Core Fund Service Shares reports 9.36% decrease in ownership of CPRX / Catalyst Pharmaceuticals, Inc.

On May 29, 2026 - GMSMX - GuideMark(R) Small/Mid Cap Core Fund Service Shares filed a NPORT-P form disclosing ownership of 6,138 shares of Catalyst Pharmaceuticals, Inc. (US:CPRX) valued at $151,977 USD as of March 31, 2026. The entity filed a previous NPORT-P on February 27, 2026 disclosing 6,772 shares of Catalyst Pharmaceuticals, Inc.. This represents a change in shares of -9.36% during the quarter. The current value of the position is $193,286 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-29 2026-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 6,138 -634 -9.36 152 -4.43 0.1588
2026-02-27 2025-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 6,772 -413 -5.75 158 12.06 0.1640
2025-11-26 2025-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 7,185 -936 -11.53 142 -19.89 0.1449
2025-08-28 2025-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 8,121 0 0.00 176 -10.20 0.1821
2025-05-30 2025-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 8,121 -2,096 -20.51 197 -7.98 0.2190
2025-02-26 2024-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 10,217 0 0.00 213 4.93 0.2149
2024-11-21 2024-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 10,217 0 0.00 203 28.48 0.2055
2024-08-27 2024-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 10,217 0 0.00 158 -2.47 0.1694
2024-05-29 2024-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 10,217 -618 -5.70 163 -10.99 0.1581
2024-02-28 2023-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 10,835 0 0.00 182 44.44 0.1728
2023-11-28 2023-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 10,835 0 0.00 127 -13.10 0.1329
2023-08-29 2023-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 10,835 0 0.00 146 -18.99 0.1453
2023-05-26 2023-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 10,835 0 0.00 180 -10.95 0.1919
2023-02-27 2022-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 10,835 -4,256 -28.20 202 4.15 0.2198
2022-11-29 2022-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 15,091 -3,555 -19.07 194 48.46 0.2200
2022-08-26 2022-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 18,646 0 0.00 131 -15.58 0.1418
2022-05-23 2022-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 18,646 0 0.00 155 22.22 0.1445
2022-02-25 2021-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 18,646 0 0.00 126 28.57 0.1082
2021-11-24 2021-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 18,646 2,207 13.43 99 4.26 0.0917
2021-08-25 2021-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 16,439 0 0.00 95 25.33 0.0883
2021-05-24 2021-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 16,439 0 0.00 76 38.89 0.0817
2021-02-22 2020-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 16,439 0 0.00 55 12.50 0.0631
2020-11-27 2020-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 16,439 0 0.00 49 -36.00 0.0687
2020-08-27 2020-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 16,439 5,707 53.18 76 82.93 0.1139
2020-05-29 2020-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 10,732 0 0.00 41 2.50 0.0786
2020-02-27 2019-12-31 NP Catalyst Pharmaceuticals EC 14888U101 10,732 7,374 219.59 40 135.29 0.0574
2019-11-27 2019-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 3,358 3,358 18 0.0278
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.